Laurion Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Laurion Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-250,000	Closed	-$23.7M	–	781
2024 Q1	$23.7M	Buy	+250,000	New	+$23.2M	0.2%	105
2021 Q4	–	Sell	-49,800	Closed	-$6.26M	–	759
2021 Q3	$6.26M	Sell	49,800 -1,092,700	-96%	-$141M	0.03%	320
2021 Q2	$155M	Buy	+1,142,500	New	+$150M	0.86%	23
2015 Q3	–	Sell	-195,000	Closed	-$16.4M	–	937
2015 Q2	$16.4M	Buy	+195,000	New	+$15.2M	0.15%	167

Other funds holding XBI

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

Laurion Capital Management's XBI Position: Q1 2024 in Review

Laurion Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2024, closing a stake of 9,400 shares — an estimated $872K sold.

Laurion Capital Management first reported a position in XBI in Q4 2023 and held it in 1 quarter. The position peaked at $839K in Q4 2023. 780 funds tracked by Wall St. Rank hold XBI as of Q1 2024.

Laurion Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2024 after selling out during the quarter.
Laurion Capital Management sold 9,400 State Street SPDR S&P Biotech ETF shares in Q1 2024, an estimated $872K.
Laurion Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2023 and held it in 1 quarter.
Laurion Capital Management's State Street SPDR S&P Biotech ETF position peaked at $839K in Q4 2023.
780 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2024.

Based on Laurion Capital Management's 13F filing for Q1 2024, filed 15 May 2024.